

WHAT IS CLAIMED:

1. A binding agent that specifically binds human immunoglobulin-like transcript 3 (ILT3), comprising:

(i) a heavy chain variable region (VH) comprising a heavy chain variable region CDR1 (VH-CDR1), a heavy chain variable region CDR2 (VH-CDR2), and a heavy chain variable region CDR3 (VH-CDR3) of the amino acid sequence set forth in SEQ ID NO: 123; and a light chain variable region (VL) comprising a light chain variable region CDR1 (VL-CDR1), a light chain variable region CDR2 (VL-CDR2), and a light chain variable region CDR3 (VL-CDR3) of the amino acid sequence set forth in SEQ ID NO: 124;

(ii) a heavy chain variable region (VH) comprising a heavy chain variable region CDR1 (VH-CDR1), a heavy chain variable region CDR2 (VH-CDR2), and a heavy chain variable region CDR3 (VH-CDR3) of the amino acid sequence set forth in SEQ ID NO: 117; and a light chain variable region (VL) comprising a light chain variable region CDR1 (VL-CDR1), a light chain variable region CDR2 (VL-CDR2), and a light chain variable region CDR3 (VL-CDR3) of the amino acid sequence set forth in SEQ ID NO: 118;

(iii) a heavy chain variable region (VH) comprising a heavy chain variable region CDR1 (VH-CDR1), a heavy chain variable region CDR2 (VH-CDR2), and a heavy chain variable region CDR3 (VH-CDR3) of the amino acid sequence set forth in SEQ ID NO: 111; and a light chain variable region (VL) comprising a light chain variable region CDR1 (VL-CDR1), a light chain variable region CDR2 (VL-CDR2), and a light chain variable region CDR3 (VL-CDR3) of the amino acid sequence set forth in SEQ ID NO: 112;

(iv) a heavy chain variable region (VH) comprising a heavy chain variable region CDR1 (VH-CDR1), a heavy chain variable region CDR2 (VH-CDR2), and a heavy chain variable region CDR3 (VH-CDR3) of the amino acid sequence set forth in SEQ ID NO: 109; and a light chain variable region (VL) comprising a light chain variable region CDR1 (VL-CDR1), a light chain variable region CDR2 (VL-CDR2), and a light chain variable region CDR3 (VL-CDR3) of the amino acid sequence set forth in SEQ ID NO: 110;

(v) a heavy chain variable region (VH) comprising a heavy chain variable region CDR1 (VH-CDR1), a heavy chain variable region CDR2 (VH-CDR2), and a heavy chain variable region CDR3 (VH-CDR3) of the amino acid sequence set forth in SEQ ID NO: 113; and a light

chain variable region (VL) comprising a light chain variable region CDR1 (VL-CDR1), a light chain variable region CDR2 (VL-CDR2), and a light chain variable region CDR3 (VL-CDR3) of the amino acid sequence set forth in SEQ ID NO: 114;

(vi) a heavy chain variable region (VH) comprising a heavy chain variable region CDR1 (VH-CDR1), a heavy chain variable region CDR2 (VH-CDR2), and a heavy chain variable region CDR3 (VH-CDR3) of the amino acid sequence set forth in SEQ ID NO: 115; and a light chain variable region (VL) comprising a light chain variable region CDR1 (VL-CDR1), a light chain variable region CDR2 (VL-CDR2), and a light chain variable region CDR3 (VL-CDR3) of the amino acid sequence set forth in SEQ ID NO: 116;

(vii) a heavy chain variable region (VH) comprising a heavy chain variable region CDR1 (VH-CDR1), a heavy chain variable region CDR2 (VH-CDR2), and a heavy chain variable region CDR3 (VH-CDR3) of the amino acid sequence set forth in SEQ ID NO: 119; and a light chain variable region (VL) comprising a light chain variable region CDR1 (VL-CDR1), a light chain variable region CDR2 (VL-CDR2), and a light chain variable region CDR3 (VL-CDR3) of the amino acid sequence set forth in SEQ ID NO: 120; or

(viii) a heavy chain variable region (VH) comprising a heavy chain variable region CDR1 (VH-CDR1), a heavy chain variable region CDR2 (VH-CDR2), and a heavy chain variable region CDR3 (VH-CDR3) of the amino acid sequence set forth in SEQ ID NO: 121; and a light chain variable region (VL) comprising a light chain variable region CDR1 (VL-CDR1), a light chain variable region CDR2 (VL-CDR2), and a light chain variable region CDR3 (VL-CDR3) of the amino acid sequence set forth in SEQ ID NO: 122.

2. The binding agent of claim 1, wherein (a) the VH comprises the VH-CDR1, the VH-CDR2, the VH-CDR3 of the amino acid sequence set forth in SEQ ID NO: 123; and (b) the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 of the amino acid sequence set forth in SEQ ID NO: 124.

3. The binding agent of claim 2, wherein:

(i) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 36, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 28, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 105, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 106, the VL-CDR2 comprises the amino acid

sequence set forth in SEQ ID NO: 31, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32;

(ii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 27, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 28, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 105, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 106, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 31, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32;

(iii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 33, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 34, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 105, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 106, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 31, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32;

(iv) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 27, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 35, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 105, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 106, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 31, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32; or

(v) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 37, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 38, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 107, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 108, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 41, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 42.

4. The binding agent of claim 2 or 3, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 123, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 124.

5. The binding agent of any one of claims 2-4, comprising a heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 126, and a light chain comprises the amino acid sequence set forth in SEQ ID NO: 128.
6. The binding agent of claim 1, wherein (a) the VH comprises the VH-CDR1, the VH-CDR2, the VH-CDR3 of the amino acid sequence set forth in SEQ ID NO: 117; and (b) the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 of the amino acid sequence set forth in SEQ ID NO: 118.
7. The binding agent of claim 6, wherein:
- (i) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 80, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 72, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 73, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 74, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 75, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 76;
 - (ii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 71, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 72, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 73, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 74, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 75, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 76;
 - (iii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 77, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 78, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 73, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 74, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 75, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 76;
 - (iv) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 71, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 79, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 73, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 74, the VL-CDR2 comprises the amino acid

sequence set forth in SEQ ID NO: 75, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 76; or

(v) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 81, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 82, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 83, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 84, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 85, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 86.

8. The binding agent of claim 6 or 7, wherein

(a) the VH comprises the amino acid sequence set forth in SEQ ID NO: 117, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 118;

(b) the VH comprises the amino acid sequence set forth in SEQ ID NO: 162, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 164; or

(c) the VH comprises the amino acid sequence set forth in SEQ ID NO: 163, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 164.

9. The binding agent of claim 1, wherein (a) the VH comprises the VH-CDR1, the VH-CDR2, the VH-CDR3 of the amino acid sequence set forth in SEQ ID NO: 111; and (b) the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 of the amino acid sequence set forth in SEQ ID NO: 112.

10. The binding agent of claim 9, wherein:

(i) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 36, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 28, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 29, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 30, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 31, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32;

(ii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 27, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 28, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 29, the VL-CDR1 comprises the

amino acid sequence set forth in SEQ ID NO: 30, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 31, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32;

(iii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 33, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 34, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 29, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 30, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 31, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32;

(iv) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 27, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 35, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 29, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 30, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 31, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 32; or

(v) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 37, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 38, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 39, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 40, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 41, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 42.

11. The binding agent of claim 9 or 10, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 111, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 112.

12. The binding agent of claim 1, wherein (a) the VH comprises the VH-CDR1, the VH-CDR2, the VH-CDR3 of the amino acid sequence set forth in SEQ ID NO: 109; and (b) the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 of the amino acid sequence set forth in SEQ ID NO: 110.

13. The binding agent of claim 12, wherein:

(i) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 20, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 15, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16;

(ii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 11, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 15, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16;

(iii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 17, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 18, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 15, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16;

(iv) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 11, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 19, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 15, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 16; or

(v) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 21, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 22, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 23, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 24, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 25, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 26.

14. The binding agent of claim 12 or 13, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 109, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 110.

15. The binding agent of claim 1, wherein (a) the VH comprises the VH-CDR1, the VH-CDR2, the VH-CDR3 of the amino acid sequence set forth in SEQ ID NO: 113; and (b) the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 of the amino acid sequence set forth in SEQ ID NO: 114.

16. The binding agent of claim 15, wherein:

(i) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 52, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 44, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 45, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 46, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 47, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 48;

(ii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 43, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 44, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 45, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 46, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 47, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 48;

(iii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 49, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 50, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 45, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 46, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 47, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 48;

(iv) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 43, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 51, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 45, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 46, the VL-CDR2 comprises the amino acid

sequence set forth in SEQ ID NO: 47, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 48; or

(v) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 53, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 54, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 55, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 56, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 57, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 58.

17. The binding agent of claim 15 or 16, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 113, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 114.

18. The binding agent of claim 1, wherein (a) the VH comprises the VH-CDR1, the VH-CDR2, the VH-CDR3 of the amino acid sequence set forth in SEQ ID NO: 115; and (b) the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 of the amino acid sequence set forth in SEQ ID NO: 116.

19. The binding agent of claim 18, wherein:

(i) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 52, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 59, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 60, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 61, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 62, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 63;

(ii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 43, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 59, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 60, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 61, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 62, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 63;

(iii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 49, the

VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 64, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 60, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 61, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 62, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 63;

(iv) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 43, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 65, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 60, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 61, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 62, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 63; or

(v) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 53, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 66, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 67, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 68, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 69, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 70.

20. The binding agent of claim 18 or 19, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 115, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 116.

21. The binding agent of claim 1, wherein (a) the VH comprises the VH-CDR1, the VH-CDR2, the VH-CDR3 of the amino acid sequence set forth in SEQ ID NO: 119; and (b) the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 of the amino acid sequence set forth in SEQ ID NO: 120.

22. The binding agent of claim 21, wherein:

(i) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 36, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 87, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 88, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 89, the VL-CDR2 comprises the amino acid

sequence set forth in SEQ ID NO: 90, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 91;

(ii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 27, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 87, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 88, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 89, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 90, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 91;

(iii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 33, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 92, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 88, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 89, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 90, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 91;

(iv) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 27, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 93, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 88, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 89, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 90, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 91; or

(v) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 37, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 94, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 95, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 96, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 97, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 98.

23. The binding agent of claim 21 or 22, wherein:

(a) the VH comprises the amino acid sequence set forth in SEQ ID NO: 119, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 120;

(b) the VH comprises the amino acid sequence set forth in SEQ ID NO: 156, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 161;

(c) the VH comprises the amino acid sequence set forth in SEQ ID NO: 157, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 161;

(d) the VH comprises the amino acid sequence set forth in SEQ ID NO: 158, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 161;

(e) the VH comprises the amino acid sequence set forth in SEQ ID NO: 159, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 161; or

(f) the VH comprises the amino acid sequence set forth in SEQ ID NO: 160, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 161.

24. The binding agent of claim 1, wherein (a) the VH comprises the VH-CDR1, the VH-CDR2, the VH-CDR3 of the amino acid sequence set forth in SEQ ID NO: 121; and (b) the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 of the amino acid sequence set forth in SEQ ID NO: 122.

25. The binding agent of claim 24, wherein:

(i) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 80, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 99, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 73, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 100, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 75, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 76;

(ii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 71, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 99, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 73, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 100, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 75, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 76;

(iii) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 77, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 101, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 73, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 100, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 75, and the VL-CDR3 comprises the amino acid sequence set

forth in SEQ ID NO: 76;

(iv) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 71, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 102, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 73, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 100, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 75, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 76; or

(v) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 81, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 103, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 83, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 104, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 85, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 86.

26. The binding agent of claim 24 or 25, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 121, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 122.

27. The binding agent of any one of claims 1-26, wherein the binding agent is an antibody.

28. The binding agent of claim 27, wherein the binding agent is a monoclonal antibody, a chimeric antibody, a recombinant antibody, a humanized antibody, a bispecific antibody, or a multispecific antibody.

29. The binding agent of claim 27 or 28, wherein the binding agent is an IgG1 antibody, an IgG2 antibody, or an IgG4 antibody.

30. The binding agent of any one of claims 27-29, wherein the binding agent comprises a kappa light chain constant region or a lambda light chain constant region.

31. The binding agent of any one of claims 27-30, wherein the binding agent comprises a human IgG1 constant region and a human kappa light chain constant region.

32. The binding agent of claim 31, wherein the human IgG1 constant region comprises one or more mutations that reduce or eliminate effector functions.
33. The binding agent of any one of claims 1-26, wherein the binding agent is an antibody fragment comprising at least one antigen-binding site.
34. The binding agent of claim 33, wherein the antibody fragment is a Fab, a Fab', a F(ab')₂, Fv, an scFv, an (scFv)₂, a single chain antibody, a dual variable region antibody, a diabody, or a nanobody.
35. The binding agent of any one of claims 1-34, wherein the binding agent is attached to a half-life extending moiety.
36. An isolated nucleic acid encoding the binding agent of any one of claims 1-35.
37. An expression vector comprising the nucleic acid of claim 36.
38. An isolated cell comprising the nucleic acid of claim 36 or the expression vector of claim 37.
39. An isolated cell producing the binding agent of any one of claims 1-35.
40. A pharmaceutical composition comprising (a) the binding agent of any one of claims 1-35; and (b) a pharmaceutically acceptable carrier.
41. A method of making a binding agent that specifically binds human ILT3, the method comprising:
- (a) culturing the isolated cell of claim 38 under conditions that result in the expression of the binding agent, and
 - (b) isolating the binding agent;
- optionally wherein the method further comprises formulating the binding agent as a sterile pharmaceutical composition.

42. A method of disrupting, inhibiting, or blocking the binding of ILT3 to fibronectin or fibronectin-induced ILT3 activity in a mixture of cells, the method comprising contacting the cells with the binding agent of any one of claims 1-35.
43. A method of disrupting, inhibiting, or blocking ILT3-induced suppression of myeloid cells or ILT3-induced suppression of myeloid cell activity, the method comprising contacting the myeloid cells with the binding agent of any one of claims 1-35.
44. The method of claim 43, which
- (i) restores FcR activity in the myeloid cells that express ILT3;
 - (ii) restores chemokine production by the myeloid cells that express ILT3; and/or
 - (iii) restores immune cell (e.g., T-cell) proliferation and/or activity.
45. Use of the binding agent of any one of claims 1-35 or the pharmaceutical composition of claim 39 in the manufacture of a medicament for treating cancer in a subject, wherein the binding agent of any one of claims 1-35 or the pharmaceutical composition of claim 39 is to be administered to the subject.
46. The use of claim 45, wherein
- (a) the cancer is pancreatic cancer, breast cancer, lung cancer, head and neck cancer, colorectal cancer, prostate cancer, skin cancer, melanoma, stomach cancer, gastric cancer, intestinal cancer, ovarian cancer, cervical cancer, uterine cancer, endometrial cancer, urinary bladder cancer, brain cancer, esophageal cancer, liver cancer, kidney cancer, sarcoma or testicular cancer;
 - (b) the cancer is a hematologic cancer; or
 - (c) the cancer is myelogenous leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia, or myelodysplastic syndrome.
47. The use of claim 45 or 46, wherein the binding agent is to be administered as part of a combination therapy; optionally wherein the combination therapy comprises an anti-PD-1 antibody.
48. The binding agent of any one of claims 1-35 or the pharmaceutical composition of claim 39 for use in treatment of cancer.

49. The binding agent or the pharmaceutical composition of claim 48, wherein:
- (a) the cancer is pancreatic cancer, breast cancer, lung cancer, head and neck cancer, colorectal cancer, prostate cancer, skin cancer, melanoma, stomach cancer, gastric cancer, intestinal cancer, ovarian cancer, cervical cancer, uterine cancer, endometrial cancer, urinary bladder cancer, brain cancer, esophageal cancer, liver cancer, kidney cancer, sarcoma or testicular cancer;
 - (b) the cancer is a hematologic cancer; or
 - (c) the cancer is myelogenous leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia, or myelodysplastic syndrome.
50. The binding agent or the pharmaceutical composition of claim 48 or 49, wherein the binding agent is to be administered as part of a combination therapy; optionally wherein the combination therapy comprises an anti-PD-1 antibody.
51. An antibody that binds human ILT3 and inhibits binding of human ILT3 to fibronectin, wherein the antibody has one or more of the following properties:
- (i) the antibody also binds cyno ILT3;
 - (ii) the antibody does not bind, or only weakly binds (relative to ILT3), ILT2, ILT4, ILT5, and LILRB5;
 - (iii) the antibody does not bind, or only weakly binds (relative to ILT3), LILRA1, LILRA2, LILRA4, LILRA5, and LILRA6;
 - (iv) the antibody is an ILT3 antagonist;
 - (v) the antibody inhibits ILT3 activity;
 - (vi) the antibody inhibits ILT3 signaling in cells that express ILT3;
 - (vii) the antibody inhibits binding of ILT3 to APOE;
 - (viii) the antibody inhibits binding of ILT3 to CNTFR;
 - (ix) the antibody inhibits ILT3-induced suppression of myeloid cells;
 - (x) the antibody inhibits ILT3-induced suppression of myeloid cell activity;
 - (xi) the antibody restores FcR activation in myeloid cells that express ILT3; and
 - (xii) the antibody restores chemokine production in myeloid cells that express ILT3.

52. The antibody of claim 51, which has a K_D for human ILT3 of 1 μ M to 1 pM as assessed by Biacore.
53. The antibody of claim 51 or 52, which comprises a human IgG1 constant region and a human kappa light chain constant region; optionally wherein the human IgG1 constant region comprises one or more mutations that reduce or eliminate effector functions.
54. A pharmaceutical composition comprising the antibody of any one of claims 51-53, and a pharmaceutically acceptable carrier.
55. Use of the binding agent of any one of claims 51-53 or the pharmaceutical composition of claim 54 in the manufacture of a medicament for treating cancer in a subject, the binding agent of any one of claims 51-53 or the pharmaceutical composition of claim 54 is to be administered to the subject
56. The use of claim 55, wherein the cancer is: a cancer that expresses high levels of fibronectin, a cancer expressing ILT3, pancreatic cancer, breast cancer, lung cancer, head and neck cancer, colorectal cancer, prostate cancer, skin cancer, melanoma, stomach cancer, gastric cancer, intestinal cancer, ovarian cancer, cervical cancer, uterine cancer, endometrial cancer, urinary bladder cancer, brain cancer, esophageal cancer, liver cancer, kidney cancer, sarcoma or testicular cancer, a hematologic cancer, myelogenous leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia, or myelodysplastic syndrome.
57. A combination comprising (i) a binding agent of any one of claims 1-35, or the antibody of any one of claims 51-53; and (ii) an anti-PD-1 antibody.